2016
DOI: 10.1002/med.21425
|View full text |Cite
|
Sign up to set email alerts
|

Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts

Abstract: Polyglutamine (PolyQ) diseases are a group of neurodegenerative disorders caused by the expansion of cytosine-adenine-guanine (CAG) trinucleotide repeats in the coding region of specific genes. This leads to the production of pathogenic proteins containing critically expanded tracts of glutamines. Although polyQ diseases are individually rare, the fact that these nine diseases are irreversibly progressive over 10 to 30 years, severely impairing and ultimately fatal, usually implicating the full-time patient su… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
16
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 18 publications
(17 citation statements)
references
References 382 publications
(382 reference statements)
1
16
0
Order By: Relevance
“…Studies reported that knockdown of both mATXN3 and wtATXN3 alleles using RNAi and ASO, were a doubleedged sword to SCA3/MJD models. Therefore, strategies aimed at selective silencing mutant alleles are developing rapidly [10,15,18,19,52]. In this study, we delivered paired sgRNA/Cas9n and donor DNA as modi cation templates to achieve HR repair, which was consistent with previous HD studies [24,25,53].…”
Section: Discussionsupporting
confidence: 70%
See 2 more Smart Citations
“…Studies reported that knockdown of both mATXN3 and wtATXN3 alleles using RNAi and ASO, were a doubleedged sword to SCA3/MJD models. Therefore, strategies aimed at selective silencing mutant alleles are developing rapidly [10,15,18,19,52]. In this study, we delivered paired sgRNA/Cas9n and donor DNA as modi cation templates to achieve HR repair, which was consistent with previous HD studies [24,25,53].…”
Section: Discussionsupporting
confidence: 70%
“…RNA interference (RNAi) inhibits gene expression by targeting the mRNA, which subsequently induce offtargeted sites (OTs) and degrade over time [10,11]. Antisense oligonucleotide (ASO) deletes trinucleotide expansions, via non-selective-alleles (both wild type and mutant alleles) silencing ATXN3 or HTT, is another effective strategy to cure polyQ diseases [12][13][14][15][16][17][18][19]. Although the non-selective strategy can effectively improve the neuropathological changes and motor function in HD mice, the safety risk of its application in humans cannot be excluded [19].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…These strategies include the silencing of both HTT alleles in a non-allele-selective strategy and the targeting of single-nucleotide polymorphisms (SNPs) linked to repeat expansions. The repeat region itself may be targeted in an allele selective and non-selective manner (Fiszer et al, 2012 ; Keiser et al, 2016 ; Esteves et al, 2017 ). RNA interference and antisense oligonucleotide technologies, which have been used for many years in experimental therapy for polyQ diseases, are currently complemented with genome editing systems such as the CRISPR/Cas9 (Shin et al, 2016 ; Kolli et al, 2017 ; Merienne et al, 2017 ; Monteys et al, 2017 ; Yang et al, 2017 ).…”
Section: Introductionmentioning
confidence: 99%
“…Importantly, some of these strategies alleviate polyQ toxicity in the absence of severe off-target effects, suggesting that they warrant further exploration as therapeutic approaches for the broad treatment of polyQ disorders. These studies have spurred diverse therapeutic efforts which have been recently thoroughly reviewed (Esteves et al, 2016). The extensive evidence implicating the proteasome as a therapeutic target, as well as its dysfunction and mislocalization in polyQ diseases, highlight its importance in the pathophysiology of disease.…”
Section: Proteasome Dysfunction In Polyglutamine Diseasesmentioning
confidence: 99%